Glaucoma is an irreversible form of optic neuropathy in which the optic nerve suffers damage in a characteristic manner with optic nerve cupping and retinal ganglion cell death. Primary congenital glaucoma (PCG) is an idiopathic irreversible childhood blinding disorder which manifests at birth or within the first year of life. PCG presents with a classical triad of symptoms (viz epiphora, photophobia and blepharospasm) though there are many additional symptoms, including large eye ball and hazy cornea. The only anatomical anomaly found in PCG is trabecular meshwork (TM) dysgenesis. PCG is an inheritable disease with established genetic etiology. It transmits through autosomal recessive mode. A number of cases are sporadic also. Mutations in many genes have been found to be causative in PCG and many are yet to be found. Mutations in cytochrome P4501B1 (CYP1B1) gene have been found to be the predominant cause of PCG. Other genes that have been implicated in PCG etiology are myocilin, Forkhead-related transcription factor C1 (FOXC1) and latent transforming growth factor beta-binding protein 2 (LTBP2). Mutations in these genes have been reported from many parts of the world. In addition to this, mitochondrial genome mutations are also thought to be involved in its pathogenesis. There appears to be some mechanism involving more than one genetic factor. In this review, we will discuss the various clinical, biochemical and genetic aspects of PCG. We emphasize that etiology of PCG does not lie in a single gene or genetic factor. Research needs to be oriented into a direction where gene-gene interactions, ocular embryology, ophthalmic metabolism and systemic oxidative status need to be studied in order to understand this disorder. We also accentuate the need for ophthalmic genetic facilities in all ophthalmology setups.
INTRODUCTION
Glaucoma (pronunciation: glaw-ko'me), 1 
derived from
Greek glaukos (meaning bluish-green gleam) 2 is a term referring to a collection of related disorders with complex optic nerve atrophy 3 and characteristic loss of larger retinal ganglion cells (RGC) 4, 5 leading to a consequent carbon copy pattern of loss of visual field and vision. 6 The bluish green gleam was initially observed during dilated pupil eye examinations. 7 Glaucoma has been nicknamed as 'the sneak thief of sight' and is characterized by those ocular conditions in which the intraocular pressure (IOP) is too high for the normal functioning of the optic nerve head. Previously, it was thought that glaucoma is the disease of the lens and hence the term was used for cataract. 7 Later, the term buphthalmos found its way into literature which meant the enlargement of the ocular globe that resembled the eye of an ox (Greek bous means ox). 8 Increase in the aqueous humor accumulation in the anterior chamber was recognized as an important clinical feature of glaucoma. 8 It was then
Adolf Weber who in 1856 elaborated the glaucomatous cupping of the optic disk. 8 Glaucoma is the second largest cause of blindness in the world affecting an estimated population of 60 million. 9, 10 It has been estimated that there are 1.5 to 2 million blind children in the world and a majority of them live in developing countries. 11 With regards to Indian scenario, Balasubramanian et al estimated that 1.8% of the Indian population is blind and 0.15% suffers from glaucoma. 12 Once glaucomatous blindness is precipitated, there is no known treatment to refurbish vision. As a matter of fact, blindness from glaucoma is preventable in almost all cases. What is required for this prevention is early detection and prompt treatment. Early diagnosis with genetic counseling and proper molecular workout is likely to bring down the prevalence of glaucomatous blindness. 13 If obstetricians make it a routine to observe the eyes of the neonate; early diagnosis on childhood glaucomas can be enhanced and consequent blindness hampered. There have been a few attempts to classify glaucomas but no classification system is absolute. However, glaucoma is traditionally classified on the basis of etiology (primary and secondary), anatomy of anterior chamber (open angle and closed angle), time of onset (infantile, juvenile and adult) and pathogenesis (congenital and acquired). Nevertheless, modern classification system classifies this disorder into three major groups viz (a) primary open angle glaucoma (POAG; OMIM 137760), (b) primary congenital glaucoma (PCG; OMIM 231300) and (c) primary angle closure glaucoma (PACG; no OMIM entry). Figure 1 depicts the general outline of the classification of glaucoma. The etiology of a majority of glaucoma cases is unknown 14 but many factors like increase in IOP, obstruction to aqueous humor drainage, development anomalies of anterior chamber 15, 16 and genetic susceptibility have been implicated. One of the prime focuses in our laboratory is to 
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JOCGP understand, appreciate and get an insight into the genetic etiopathology of the disease and its correlation with the so developed phenotype. We endeavor to correlate gene mutations with severity of the phenotype, age of onset, response to medical (IOP lowering drugs like -blockers) and surgical therapy (trabeculectomy/trabeculotomy) giving considerable insight into the prognosis and management of glaucoma. Genotype phenotype correlations are likely to help clinicians manage the disease better and the genetic counselor to help inflicted families with the disease management.
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PRIMARY CONGENITAL GLAUCOMA
Primary congenital glaucoma (PCG; OMIM 231300; provided in the public domain by National center for Biotechnology Information, Bethesda, MD) is an autosomal recessively inherited severe form of glaucoma resulting from obstruction in the aqueous humor drainage due to congenital developmental anomalies in anterior chamber angle/angle structures. [17] [18] [19] It accounts for 22.2% of all pediatric glaucoma cases. Congenital buphthalmos has early history having been recognized since the time of Hippocrates (460-377 BC), Celsus (1st century CE) and Galen . Buphthalmos is a result of the distensibility of the neonatal eye ball. This distensibility in the neonatal eye ball is because of the high content of elastic fibers in sclera. The mechanism of buphthalmos includes global delocalized stretching of the sclera, optic nerve and the related structures due to increased IOP. 20, 21 The normal range for corneal diameter of a neonate is 10 to 10.5 mm which, owing to growth, increases by 0.5 to 1.0 mm in first year of life. 22 Any increase in corneal diameter (>12 mm) in the first year of life is suggestive of PCG. 21 Additionally, the optic nerve cupping being one of the hallmarks of glaucoma; in case of PCG, the optic nerve changes are not similar to that of glaucomatous adults. Optic nerve cupping may progress fast and early in newborns and toddlers 23, 24 and can be reversible if normal IOP is restored well in time. 25 On the other hand, glaucomatous optic nerve head damage is irreversible in adults. 24 PCG has its onset at as early as birth or manifests within first 3 years of life. 26 It presents with a classical triad of symptoms viz epiphora (excessive tearing), photophobia (hypersensitivity to light) and blepharospasm (inflammation of the eyelids). 21 Any combination of these symptoms are indicative (if not conclusive) of glaucoma. These symptoms are caused by the irritation of cornea leading to corneal epithelial edema and haze (clouding). Enlargement of eye (buphthalmos) is a result of increased IOP. The other findings include: (i) iris covering a variable portion of ciliary body and trabecular meshwork (TM), 19, 27 (ii) thickened trabecular beams in trabeculum 28 as schematically depicted in Figure 2 , (iii) juxtacanalicular meshwork with very small number of pores, 29, 30 (iv) absence of sinus venosus eye (i.e.
Schlemm's canal) 17, 31 and (v) breaks in Descemet's membrane (Haab's striae). 7 A collection of the symptoms of PCG are depicted in Table 1 . The term PCG has been restricted to the cases where only anatomical defect observed is isolated trabecular dysgenesis. 32 This is also referred to as isolated congenital glaucoma. 33 A characteristic cloudiness or foggy manifestation of the cornea can be observed in early stages which appear before any breaks in the Descemet's membrane are visible. PCG comprises 4.2% of all childhood blindness being bilateral in 80% of cases. PCG cases presented within first year of life form more than 80% out of which 25% are diagnosed in the neonatal period and about 60% within first 6 months of life. Being the most common pediatric glaucoma, PCG comprises more than 55% of primary pediatric glaucomas with expression and penetrance varying from 40 to 100%.
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Genetics of PCG
The first report on genetic predisposition to glaucomas was published in 1842 when Benedict observed two sisters suffering from glaucoma. 35 Afterward, many reports came to the limelight suggesting a definite role of genetic factors. [36] [37] [38] PCG is inherited in an autosomal (of chromosomes other than sex chromosomes) recessive mode of transmission. Association of congenital glaucoma with chromosomal abnormalities of at least 17 different autosomes has also been reported in literature. 39 Congenital glaucoma being associated with chromosomal aberrations has been well documented in many reports. [40] [41] [42] To quote examples, congenital glaucoma with 22p+ variant chromosome has been reported in a study of Indian population. 42 Another study has observed various chromosomal anomalies, such as trisomy 8q22-qter/monosomy 9p23-qter in Australian population. 43 Additionally, Mitchell et al 44 has observed 4q deletion in Axenfeld-Rieger's syndrome (ARS). We have also reported 4q deletion in a case of ARS. 45 Moore et al reported 11p deletion in aniridia (absence of iris). 46 The genetic basis of PCG remains idiopathic but 13 chromosomal loci (GLC1A to GLC1N) for the POAG and 64 Prevalence among males accounts for 65% of total number of cases. 65 In an early study from Japan females were, conversely, reported to be having higher prevalence. 66 On the other hand, males and females were reported to be equally affected in Europe and USA. 67 In a study, on 616 cases of congenital glaucoma where patients were divided into two groups (one with sporadic cases and other with familial), it was observed that, in the first group there were 70% of males and the second group comprised of 58% males. PCG has been shown to display a definite pattern of inheritance in 30 to 40% cases 67 but some investigators have reported familial incidence of only 11 to 14%. 68 There are, nonetheless, so many facts and observations that indicate the autosomal mode of transmission of PCG with a penetrance of 40 to 100%. The autosomal recessive mode of PCG transmission has been demonstrated in rabbits [69] [70] [71] and dogs. 72 Intermediate inheritance has also been reported in rabbits. 73 One more observation supporting the autosomal recessive means of inheritance is that, in PCG, the incidence of consanguinity of the parents overshoots 8%. 74 There are so many studies that support this observation. 68, [75] [76] [77] [78] Moreover, in most of the PCG cases, two or more siblings are affected with normal parents and descendents. 68, 74, 76 A classical report by Gianferrari and his coinvestigators document two most characteristic pedigrees in which the first consisted of 11 cases of buphthalmos and two consanguineous marriages with three affected children out of four and two out of 12. 75 And, in case of the other pedigree, there were five cases of congenital glaucoma and two consanguineous marriages with two affected children out of four and one out of six.
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A peculiar finding in these pedigrees supporting autosomal recessive mode of inheritance is that the parents were phenotypically normal in all these cases. PCG is mostly sporadic with variable penetrance. 7, 33, 68, 75, [79] [80] [81] [82] [83] These observations are thought to exist because of genetic heterogeneity. 51, 84 The genetic heterogeneity studies for PCG started in early 1990s and the first locus for PCG (GLC3A) was mapped to chromosomal location 2p21 in 1995 by Sarfarazi et al. 60 The investigators described the involvement of this locus in 11 of the 17 Turkish families studied. They performed haplotype analysis and homozygosity mapping which led to the mapping of the diseased gene within 2.5 cM interval flanked by two DNA marker regions viz D252186 and C251346. Since this was the first chromosomal locus identified to be associated with PCG, it was designated 'GLC3A' (GLC: glaucoma, 3: congenital, A: first locus identified) as per the nomenclature 61, 62 Since only 11 of the 17 Turkish families were found to be having involvement of 2p21 region in their disease phenotype, it was therefore, logical to think that at least one more locus existed to account for the remaining six families. On this premise, the investigators performed haplotype analysis of these six families and successfully mapped the disease locus of four of these families to the chromosomal location 1p36 within in gene interval of 3 cM. This locus was found to be flanked by two sets (six in total) of DNA marker regions viz D151597/D15485/D15228 and D151176/D15508/D15407. There are many tumor suppressor genes in this region. 85 Being the second locus to be mapped, it was designated 'GLC3B'. 52 A very large number of genes have been found to be located in 1p36 region but none has been postulated as a causative factor for PCG. This region is very prone to chromosomal aberrations resulting in many malignant diseases. Also, the neighboring regions of 1p36 quite often participate in recombination events. 86 Since the identification of genetic locus for two of the 17 families still remained, it meant that at least one more genetic locus remains to be mapped. The multigeneration pedigree analysis of one of those remaining two families revealed a third PCG locus with chromosomal location 14q24.3 within a region 2.9-cM narrow. 53 Being the third in the chronology of mapping, this locus was designated 'GLC3C'. Using the genome-wide scanning approach, the investigators were able to identify the DNA markers region D14553. Using additional DNA markers in haplotype analysis, it was found that all PCG patients shared DNA marker regions of homozygosity including D14542/ D145983/D1451020 and D14574.
Polygenic Inheritance of PCG
Before going on to discuss the genes involved and implicated in PCG, it forms a good rationale to add a note about its polygenic inheritance. PCG is not a unigenic etiological outcome but rather multifactorial genetic phenotype. Many genes (CYP1B1, MYOC, FOXC1, LTBP2, etc.) have been found to be involved in its etiology but there remains a great spectrum to be identified. Mutations in CYP1B1 gene account for a very little percentage of total number of PCG cases, it is logical for that reason to speculate about the role of other genes in PCG development and pathogenesis. There are a number of studies which suggest that the bequest of PCG is polygenic (involving more than one gene as an etiological factor). These genes may have functional interactions among themselves and may, for that reason, act in synergy with each other leading to the development of anterior chamber ocular structures. Any violation of the harmony anywhere in the functional muddle of these genes may give rise to anomalies in the anterior chamber anatomy and, therefore, to PCG. Polygenic inheritance can be explained via many reasons, such as variable penetrance observed in these cases and varied prevalence with respect to sex in different population. There are, however, some studies which suggest that there are no gender-wise differences in prevalence of PCG. 82 As we will discuss in this review that many genes have been implicated in etiology of PCG, the polygenic etiology of this disorder is well confirmed. Functional interaction between CYP1B1 gene and MYOC gene further lends support to this.
Cytochrome P450, Family 1, Subfamily B, Polypeptide 1 (CYP1B1) Gene and PCG
The cytochrome P450 superfamily consists of as many as 70 gene families spanning across bacteria, yeasts, insects and vertebrates as well as plant kingdom. 87 Fourteen mammalian families of P450 have been observed till date, out of which, five have been reported to have many subfamilies. Formerly, it was thought that cytochrome-P4501B1 family is composed of two members viz CYP1A1 and CYP1A2. 87 The genes of this family are ubiquitous in mammals and have comparable catabolic activities toward a great number of xenobiotics. CYP1B1 is the third member of this family which has been recently characterized. CYP1B1 gene (GenBank accession no. U56438), therefore, forms a member of the superfamily of drug metabolizing enzymes cytochrome-P450 (CYP450). The CYP450 family is inclusive of 58 functional genes in humans and 102 in mice. 88 Initially, this gene was recognized as a dioxinresponsive cDNA clone. The activities of this gene against various xenobiotics and metabolic approaches toward many procarcinogens have been thoroughly explored. 89 In one of the approaches, TCDD (2,3,7,8-tetrachlorodibenzo-pdioxin) responsive cDNA was isolated from a human keratinocyte cell line and established as a new cytochrome P450 superfamily member. 89 The translation product of this gene designated as cytochrome P4501B1 (CYP1B1) has also been cloned and characterized from mouse 90 and rat. 91 It is interesting to note that the size of rodent and human CYP1B1 mRNA is almost equal (5.2 kB in mice and 5.1 kB in humans). Furthermore, both rodent and human CYP1B1 code for a protein 543 amino acids long. CYP1B1 is constitutively expressed in adrenal glands, ovaries, testes and more than 15 other tissues of the body. Its expression can be upregulated by aromatic hydrocarbons, adrenocorticotropin and peptide hormones. 89, 92 This protein plays In humans, the CYP1B1 gene consists of three exons (with open reading frame starting from exon II) and two introns and is 8.5 kB long. These three exons are 371, 1,044 and 3,707 base pairs in length respectively. Conversely, the two introns are 390 and 3,032 base pairs long. Both the introns commence with the sequence GT… and end with the sequence ...AG. The upstream regions of introns are pyrimidine rich, the coding region of CYP1B1 gene starts at the 5' end of 2nd exon and ends within the last exon. The translation product of CYP1B1 gene is 543 amino acids (corresponding to 1,629 bases) long protein with 53 residue membrane bound N-terminal, 10 residue proline rich hinge (contributing to the flexibility of the protein) and 480 amino acid long cytosolic globular domain. The carboxy terminal region of CYP1B1 is highly conserved suggesting a pivotal role of this region. The carboxy terminal of cytochrome p450 enzymes corresponds to a set of conserved core structures (CCS) for the heme-binding region essential for the normal functioning of this class of enzymes. Figure 3 illustrates a schematic diagram of CYP1B1 gene. The CYP1B1 is a single copy gene as confirmed by the southern analysis studies using DNA probes to all three exons. It differs significantly from its close relatives CYP1A1 in CYP1A2. CYP1A1 and CYP1A2 both have seven exons as against three in CYP1B1 with former being located on chromosome 15 and the latter on chromosome 2. CYP1B1 gene lacks a consensus TATA box in the promoter region and contains nine TCDD responsive enhancer regions (5'-GCGTG-3') located within a 2.5 kB upstream. Deletion analysis studies with chloramphenicol acetyltransferase reporter gene constructs containing 5'CYP1B1 genomic fragment indicated that an upstream region from -1,002 to -835 contains core binding motifs contributing to the TCDD inducible expression. CYP1B1 is expressed in many tissues including brain and breast secretary cells 95 and almost in 15 other nonocular tissues. 89 In its metabolic pathway, CYP1B1 generates molecular species which operate through some signaling pathways and regulate expression of a spectrum of genes implicated in growth, development and differentiation of different ocular structures. CYP1B1 gene product also metabolizes vitamin A in two steps to alltransretinal (aldehyde form) and all-transretinoic acid (carboxylic acid form). 96 All-transretinoic acid is an effective morphogen and regulates in utero (fetal) development, growth and differentiation. 97 The CYP450 Table 4 enlists the novel mutations reported by our laboratory with their corresponding GenBank accession numbers and likely effect on the corresponding protein function. Our study constitutes the first CYPIB1 mutational spectrum report for PCG from northern India. 104 Mutations in CYP1B1 gene have been described as the main underlying genetic etiology for majority of PCG cases in Turkish and Saudi Arabian families. 62 European,
Canadian and Slovakian families suffering from PCG have also been report to harbor mutations in CYP1B1 gene.
106 Figure 4 illustrates the worldwide distribution of CYP1B1 mutations in PCG patients and a comprehensive country wise list has been shown in The number of reports of allelic heterogeneity at GL3CA locus is increasing very fast. Three-dimensional model structure analyses have revealed that most of the nonsynonymous mutations affect the relatively conserved carboxyl half of the CYP1B1 protein leading to derangements in the core structure of the enzyme. 114 This, therefore, makes a good rationale to think that these mutations affect the functional properties of the enzyme like substrate recognition, etc. Our studies, for this reason, are currently focused on functional characterization of CYP1B1 mutations. The CYP1B1 polymorphism is most likely to be conserved; however, some modulations are possible within certain limits. In Saudi Arabia, the mutations G61E accounts for almost 70% of the PCG cases. 61, 108, 115 Interestingly, E387K mutation was found in 43 patients who could be traced to a common ancestor. 115 Stoilov et al reported 4340delG mutation in 20.2% of PCG cases in Brazil. 112 Till date, at least 147 different CYP1B1 mutations have been identified all over the world in 542 PCG patients 103 and the list is growing with increasing number of reports. These include deletions, insertions missense, nonsense, frameshift as well as truncating mutations and a mutation in noncoding region of exon I. Table 3 gives a comprehensive update on the exon-wise distribution of CYP1B1 mutations in PCG patients. Studies suggest that the most severe phenotype is associated with the frameshift mutations. 116 The mutational spectrum of CYP1B1 gene in different population and its consequent correlation with etiology and pathogenesis of PCG has lead to the idea that CYP1B1 enzyme is important for development of the anterior chamber of eye. CYP1B1 protein has been found to be present in higher levels in fetal ocular structure as compared to adult eye, therefore, lending support to the idea. Since ciliary body secretes metalloproteases (an enzyme whose catalytic activity requires a metal ion), CYP1B1 having metabolic influence on these secretions can influence IOP. 117 Additionally, CYP1B1 (-/-) mice (also designated as CYP1B1 null mice) have on the contrary of the belief been found to be nonglaucomatous with normal anterior chamber. But electron microscopy of the anterior chamber structure of such mice has revealed hypoplasia of the TM, abnormally placed basal lamina and iridocorneal adhesions. 118 More recent reports have, on the other hand, reported elevated IOP in CYP1B1(-/-) mice. 119 Also, CYP1B1 mutations in presence of tyrosinase (TYR) deficiency (129 x1/SvJ) develop into a more severe phenotype immediately suggesting TYR as a modifier gene. 118 TYR deficiency is also found in patients with anterior segment dysgenesis (ASD) and albinism. 120 Therefore, in addition to identifying other loci and genes as agents behind pathogenesis of PCG, gene-gene interaction studies might lead to proper understanding of the disease pathogenesis and consequently revealing probable mechanism for required therapy.
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Myocilin/TIGR Gene (Myocilin/Trabecular Meshwork Inducible Glucocorticoid Response Protein) and PCG
MYOC gene belongs to the family of the soluble Nethylmaleimide sensitive factor attachment protein receptor This study also included French and Portuguese patients; This study also included Hispanic, Middle Eastern and Caucasian patients; This study also included Italian and Indian patients; This study also included American, French, British and Turkish patients; This study also included Sudanese, Turkish and Italian patients; This study also included Costa Rican, Turkish, German, Swiss, American and Saudi Arabian patients; This study also included Egyptian patients (SNARE). The proteins of SNARE family function as vesicle trafficking and targeting factors thereby serving as molecular addresses on secretory vesicles. 121 The MYOC gene codes for a protein that was initially named trabecular meshwork inducible glucocorticoid response protein (TIGR). This gene has been mapped to chromosomal locus 1q23-24 122 with physical map between four contiguous genes viz SELL, SELE, APT1LG1 and AT3. 123 Owing to its similarities with bullfrog olfactomedin and Dictyostelium discoideum myosin as per the sequence analogy, this protein was named myocilin by Kubota et al. 124 MYOC spans an approximate of 20 kB and like CYP1B1 has three exons [116] [117] [118] 
Forkhead-related Transcription Factor C1
FOXC1 is another potential etiological factor implicated in PCG pathogenesis. It is Forkhead-related transcription factor C1 (FOXC1 or FKHL7) and is located on p-arm of chromosome 6 (locus 6p25). See Figure 6 for a schematic representation of FOXC1 gene. FOXC1 mutations in PCG recently got attention. FOXC1 mutations were previously known to be directly involved in eye conditions collectively referred to as ASD. As TM (tissue deranged in PCG) is the part of the anterior segment, it is logical to think of its role in PCG development and pathogenesis. In our studies, we found two sequence variations viz GGC375ins and GGC447ins in FOXC1 gene in PCG patients who did not harbor mutations in CYP1B1 gene. However, it is worth mentioning that no significant correlation could be observed 
Other Genes
Other genes thought to play a role in the pathogenesis of PCG are optineurin (OPTN), WDR36, LOXL1, PAX6, PITX2, etc. but no conclusive report to confirm their role in PCG etiology has come about. However, it is sure that the more we advance in the studies of PCG; we are likely to identify many more genes having role in the etiology of this disorder as well as other related disorders termed as ASD. There is a very high concentration of mitochondria present in the cells of optic nerve head presumably because of the requirement of higher amount of energy as compared to other tissues. Hence, the very survival of the RGCs of the optic nerve head depends on its mitochondria 137 Being involved in apoptosis, calcium signaling and metabolism of reactive oxygen species (ROS); mitochondria form the imperative organelles for the survival of RGCs. It is well known that mitochondrial dysfunction/malfunction leads to increase in oxidative stress (OS) consequently ensuing damage to ETC enzymes, genomic DNA, mt-DNA and impairment in regulating calcium. This gamut of derangements results in neuronal degeneration 138 finally precipitating glaucoma and other related conditions. The observation that glaucoma is accompanied by increase in OS and decrease in antioxidant activity appends further support to this idea. 139 OS elevation leads to injury in the anterior segment structures of the eye. 140 Furthermore, it has been observed that oxidative damage to TM is increased in glaucomatous patients 136 causing increased IOP (one of the main etiological factors for PCG). Up until now, numerous studies have been published which suggest mitochondrial dysfunction as the etiological factors for various glaucomas. 138, 141, 142 All these factors may be involved directly or indirectly in PCG. Abu Amero et al 136 and Izzoti et al 143 reported that mutations in mt-DNA are 
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JOCGP present in cases of PACG. Further, an increased frequency of mutations in mt-DNA has been reported in POAG, PACG as well PEG cases. 144, 145 With regards to PCG, we compared 35 PCG patients with 40 controls and screened them for mutations in mitochondrial genome by analyzing the sequences against reference sequence NC-012920. We found that 22.85% PCG patients had potentially pathogenic sequence changes in mt-DNA (as per the PolyPhen and SIFT analysis) and 57.14% had sequence changes associated with increase in ROS. 146 In these studies, the mitochondrial sequence variations in PCG patients were very high as compared to the controls, therefore, establishing mitochondria as the hot spot for etiology of PCG. In our other studies, we found the similar results. 147 We have also proposed the probable mechanism for mitochondrial mutation induced TM dysgenesis.
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CONCLUSION
PCG is a complex neurodegenerative disorder with established genetic etiology. It is mainly inherited through autosomal recessive mode of inheritance. The number of chromosomal aberrations, many chromosomal loci identified and a great variety of genes involved make PCG an intricate eye condition with multifarious etiologies and consequently diverse pathogenic mechanisms. This diversity in pathogenesis accounts for the variable penetrance observed in PCG. Though a good number of studies have been published but many more rigorously investigative strategies need to be developed in order to get further insight into this blinding disorder. Many studies about the mutational spectrum of PCG in different population are being continuously reported. This will aid in correlating pathogenic mutations with the disease phenotype. The more we know about the pathogenesis of this disease, the more effectively its management strategem can be planned so that patients and their relatives are counseled with respect to risk factors. This may improve the outcome of the management regimens. Molecular evaluation of PCG is necessary and screening of high risk group can lead to good outcomes. With regards to mitochondrial mutations and increased OS, prompt antioxidant therapy and genetic counseling will and should form an essential part of glaucoma therapy in near future though gene therapy regimen is yet far from being a reality. In near future, recombinant CYP1B1 proteins might find a therapeutic role in PCG management if the CYP1B1 mutation in a patient is identified. Moreover, stem cell therapy with the correct copy of the implicated genes may be a promising regimen if the molecular mechanism of PCG is worked out in detail. Additionally, understanding the etiology, pathogenesis, mechanism and mode of PCG inheritance can help in devising counseling strategies to keep family members and children of affected members at bay. Additionally, marriage counseling can also be practiced to bring down the prevalence of PCG particularly in consanguineous societies. It is, therefore, endorsed that every ophthalmology hospital should have a separate unit for genetic evaluation, molecular workout and genetic counseling of patients suffering from PCG and other related ocular diseases.
